Loading...
Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate-associated neutropenia
AIMS: Eribulin mesilate is an inhibitor of microtubule dynamics that is approved for the treatment of late-stage metastatic breast cancer. Neutropenia is one of the major dose-limiting adverse effects of eribulin. The objective of this analysis was to develop a population pharmacokinetic–pharmacodyn...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Blackwell Science Inc
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3769668/ https://ncbi.nlm.nih.gov/pubmed/23601153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|